Robert Zivadinov1,2, Kiren Kresa-Reahl3, Bianca Weinstock-Guttman4, Keith Edwards5, Chakkarin Burudpakdee6, Niels Bergsland1, Michael G Dwyer1,2, Bhupendra Khatri7, Karthinathan Thangavelu8, Jeffrey Chavin8, Matt Mandel8, Stanley Cohan3. 1. Buffalo Neuroimaging Analysis Center, University at Buffalo, Buffalo, NY, USA. 2. Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, Buffalo, NY, USA. 3. Providence Multiple Sclerosis Center, Providence St Joseph Health, Portland, OR, USA. 4. Jacobs Comprehensive MS Center for Treatment & Research, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. 5. Multiple Sclerosis Center of Northeastern New York, NY, USA. 6. IQVIA, Fairfax, VA, USA. 7. Wheaton Franciscan Healthcare, Center for Neurological Disorders, Milwaukee, WI, USA. 8. Sanofi, Cambridge, MA, USA.
Abstract
AIM: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. OBJECTIVES: To compare the real-world effectiveness of TFM versus DMF. METHODS: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50). RESULTS: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals. CONCLUSION: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
AIM: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. OBJECTIVES: To compare the real-world effectiveness of TFM versus DMF. METHODS: Anonymized data were collected from patients with relapsing multiple sclerosis (MS) initiating treatment with teriflunomide (N = 50) or DMF (N = 50). RESULTS: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30.0 versus 40.0% (p = 0.2752). However, median annualized percent whole brain volume change was -0.1 versus -0.5 (p = 0.0212). There were no significant treatment differences on additional MRI and clinical end points and no unexpected safety signals. CONCLUSION: The effectiveness of teriflunomide was superior to DMF on whole brain atrophy and similar to DMF on other MRI/clinical end points.
Entities:
Keywords:
MRI; brain volume; dimethyl fumarate; relapsing forms of MS; retrospective study; teriflunomide
Authors: Robert Zivadinov; Michael G Dwyer; Ellen Carl; Elizabeth M Poole; Steve Cavalier; Paraskevi Briassouli; Niels Bergsland Journal: Ther Adv Neurol Disord Date: 2020-11-11 Impact factor: 6.570